Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Jun 24:13:937555.
doi: 10.3389/fimmu.2022.937555. eCollection 2022.

Gut Microbiota: A Novel Therapeutic Target for Parkinson's Disease

Affiliations
Review

Gut Microbiota: A Novel Therapeutic Target for Parkinson's Disease

Manlian Zhu et al. Front Immunol. .

Abstract

Parkinson's disease (PD) is the second most common neurodegenerative disease characterized by motor dysfunction. Growing evidence has demonstrated that gut dysbiosis is involved in the occurrence, development and progression of PD. Numerous clinical trials have identified the characteristics of the changed gut microbiota profiles, and preclinical studies in PD animal models have indicated that gut dysbiosis can influence the progression and onset of PD via increasing intestinal permeability, aggravating neuroinflammation, aggregating abnormal levels of α-synuclein fibrils, increasing oxidative stress, and decreasing neurotransmitter production. The gut microbiota can be considered promising diagnostic and therapeutic targets for PD, which can be regulated by probiotics, psychobiotics, prebiotics, synbiotics, postbiotics, fecal microbiota transplantation, diet modifications, and Chinese medicine. This review summarizes the recent studies in PD-associated gut microbiota profiles and functions, the potential roles, and mechanisms of gut microbiota in PD, and gut microbiota-targeted interventions for PD. Deciphering the underlying roles and mechanisms of the PD-associated gut microbiota will help interpret the pathogenesis of PD from new perspectives and elucidate novel therapeutic strategies for PD.

Keywords: Parkinson’s disease; diet; gut microbiota; microbiota-targeted therapy; α-synuclein.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
The schematic representation of the gut microbiota dysbiosis associated with parkinson’s disease. Microbiota dysbiosis plays vital roles in the occurrence and developemnt of parkinson’s disease. Dysbiotic gut microbiota was associated with the increased intestinal permeability, aggravated neuroinflammation, abnormal aggregation of α-synuclein fibrils, oxidative stress, and decreased neurotransmitter production, which played vital roles in the ocurrence and development of Parkinson’s disease. Several microbota-targeted therapies can be used to modify the composition of the gut microbiota to revert a dysbiotic condition: probiotics, psychobiotics, prebiotics, synbiotics, postbiotics, fecal microbiota transplantation, dietary modifications and Chinese medicines.

References

    1. Lajoie AC, Lafontaine AL, Kaminska M. The Spectrum of Sleep Disorders in Parkinson Disease: A Review. Chest (2021) 159(2):818–27. doi: 10.1016/j.chest.2020.09.099 - DOI - PubMed
    1. Gbd 2016 parkinson's disease collaborators . Global, Regional, and National Burden of Parkinson's Disease, 1990-2016: A Systematic Analysis for the Global Burden of Disease Study 2016. Lancet Neurol (2018) 17(11):939–53. doi: 10.1016/s1474-4422(18)30295-3 - DOI - PMC - PubMed
    1. Okunoye O, Marston L, Walters K, Schrag A. Change in the Incidence of Parkinson's Disease in a Large UK Primary Care Database. NPJ Parkinsons Dis (2022) 8(1):23. doi: 10.1038/s41531-022-00284-0 - DOI - PMC - PubMed
    1. Dorsey ER, Sherer T, Okun MS, Bloem BR. The Emerging Evidence of the Parkinson Pandemic. J Parkinsons Dis (2018) 8(s1):S3–s8. doi: 10.3233/jpd-181474 - DOI - PMC - PubMed
    1. Tolosa E, Garrido A, Scholz SW, Poewe W. Challenges in the Diagnosis of Parkinson's Disease. Lancet Neurol (2021) 20(5):385–97. doi: 10.1016/s1474-4422(21)00030-2 - DOI - PMC - PubMed

Publication types